Brokerages expect BIOLINERX Ltd/S (NASDAQ:BLRX) to announce earnings per share (EPS) of ($0.05) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for BIOLINERX Ltd/S’s earnings. BIOLINERX Ltd/S posted earnings of ($0.07) per share in the same quarter last year, which suggests a positive year over year growth rate of 28.6%. The business is expected to issue its next quarterly earnings report on Tuesday, November 20th.
According to Zacks, analysts expect that BIOLINERX Ltd/S will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.22) to ($0.21). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.26) to ($0.22). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover BIOLINERX Ltd/S.
BIOLINERX Ltd/S (NASDAQ:BLRX) last released its earnings results on Monday, August 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.
BLRX has been the subject of a number of recent analyst reports. HC Wainwright set a $4.00 target price on shares of BIOLINERX Ltd/S and gave the company a “buy” rating in a report on Tuesday, August 7th. Maxim Group restated a “buy” rating and issued a $2.00 target price on shares of BIOLINERX Ltd/S in a report on Monday, August 13th. ValuEngine upgraded shares of BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Zacks Investment Research upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Thursday, August 16th. Finally, MED initiated coverage on shares of BIOLINERX Ltd/S in a report on Wednesday, August 1st. They issued a “market perform” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $2.50.
BIOLINERX Ltd/S stock traded down $0.10 during trading on Friday, reaching $0.98. The company had a trading volume of 21,143 shares, compared to its average volume of 352,240. BIOLINERX Ltd/S has a 12-month low of $0.78 and a 12-month high of $1.34. The company has a market cap of $99.06 million, a price-to-earnings ratio of -3.63 and a beta of 0.58.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: How Do Tariffs Affect Trade Balances?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.